Investors Target BioMimetic Over Bone Graft Statements

Law360, New York (August 15, 2011, 3:17 PM EDT) -- BioMimetic Therapeutics Inc. shareholders sued the biotechnology company Friday in Tennessee federal court, accusing its executives of puffing up the results of clinical trials for its star product, a synthetic bone graft.

BioMimetic's lead product candidate is Augment, a synthetic bone graft for use in foot and ankle fusion surgery. Although the company and its executives touted the new bone graft in regulatory filings and press releases, they knew that there were serious problems with it that the U.S. Food and Drug Administration ultimately revealed, according...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Duvall v. Lynch et al


Case Number

3:11-cv-00775

Court

Tennessee Middle

Nature of Suit

Stockholders Suits

Judge

Kevin H. Sharp

Date Filed

August 12, 2011

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.